healthmedicinet

Johnson Johnson today announced that its subsidiary, Janssen Research and Development, LLC, has entered into a novel agreement with Yale School of Medicine’s Open Data Access (YODA) Project that will extend its commitment to sharing clinical trials data to enhance public health and advance science and medicine. Under the agreement, YODA will serve as an independent body to review requests from investigators and physicians seeking access to anonymized clinical trials data from Janssen, the pharmaceutical companies of Johnson Johnson, and make final decisions on data sharing. This is the first time any company has collaborated with a completely independent third party to review and make decisions regarding every request for clinical data.

“Sharing anonymized data from clinical trials is critical to advance public health because it furthers our understanding of diseases, expands the base of knowledge needed to develop new treatments, and generates new insights and more complete evidence to enable better healthcare decisions for patients – all while protecting patient privacy and confidentiality,” said Joanne Waldstreicher, MD, Chief Medical Officer, Johnson Johnson. “We are pleased to collaborate with YODA to ensure that each and every request for access to our pharmaceutical clinical data is reviewed objectively and independently. This represents a new standard for responsible, independent clinical data sharing.”

Under the agreement, YODA will independently review and make final decisions regarding all requests for the company’s clinical trial data including clinical study reports (CSRs) and de-identified patient-level data.  While YODA members may reach out to Janssen researchers with questions, the final decision on data sharing will be made by YODA. Members of the YODA team at Yale School of Medicine will select and appoint an independent external panel of non-Janssen experts to help in some cases to assess requests.

In addition to Janssen’s sharing of data from pharmaceutical product clinical trials through the agreement with YODA, Johnson Johnson is also committed to the sharing of data from clinical trials of the medical device and consumer products of the Johnson Johnson family of companies. 

“Responsible sharing of clinical trial data advances science and medicine and is part of Johnson Johnson’s commitment to the doctors, nurses, patients, mothers, and fathers and all others who use our products,” said Paul Stoffels, MD, Chief Scientific Officer, Johnson Johnson Worldwide Chairman, Pharmaceuticals. “Our agreement with YODA exemplifies the Johnson Johnson family of companies’ commitment to science, medicine and public health by creating a standardized independent, transparent and reproducible process for sharing our clinical trial data.”